Head and Neck Cancer Study Project in the Geriatric Population

This is a study conducted in patients with a diagnosis of stage IB-IVA squamous cell carcinoma of the head and neck. Patients will have a comprehensive geriatric assessment (CGA) as part of standard assessments. The patients classified as frail, with a CGA score of 3-5, will then be treated with a novel reduced intensity regimen. The regimen will be tailored based on the programmed cell death ligand 1 combined positive score (PD-L1 CPS) and will involve 4 cycles of systemic chemotherapy and/or immunotherapy followed by radiation treatment.

Trial Details

NCT ID
NCT06998069
Phase
PHASE3
Sponsor
Brown University
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Arm I Carboplatin, Paclitaxel, Pembrolizumab
  • Arm II Carboplatin, Paclitaxel, Cetuximab
  • Arm III Pembrolizumab
Locations (sample)
  • Providence, Rhode Island, United States|41.82399,-71.41283

Key Eligibility Criteria

  • Patients must have the following
  • Pathology confirmed squamous cell carcinoma of the head and neck (unknown primary is excluded).
  • Confirmed stage of disease between IB and IVA, based on imaging studies.
  • CGA score of 3-5

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →